Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Richard C Duke

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
    Other Positions
    TitleProfessor
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-MED
    DivisionONC GENERAL OPERATIONS


    Collapse Research 
    Collapse research activities and funding
    R44CA268313     (GONZALEZ, RENE)Sep 1, 2022 - Aug 31, 2024
    NIH
    Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
    Role: Co-Principal Investigator
    U01HL152405     (DUKE, RICHARD C)Sep 23, 2019 - Aug 31, 2023
    NIH
    Colorado AMC REACH Hub
    Role: Principal Investigator
    U01AI070821     (DUKE, RICHARD C)Aug 15, 2006 - Jul 31, 2009
    NIH
    Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics
    Role: Principal Investigator
    R43AI043143     (DUKE, RICHARD C)Sep 30, 1998 - Mar 31, 2000
    NIH
    USING LIVE, RECOMBINANT BAKERS YEAST AS AN HIV VACCINE
    Role: Principal Investigator
    R21AI042688     (DUKE, RICHARD C)Sep 30, 1997 - Sep 29, 2000
    NIH
    NOVEL, LIVE, RECOMBINANT YEAST BASED HIV VACCINE
    Role: Principal Investigator
    R01AI040607     (DUKE, RICHARD C)Dec 1, 1996 - Nov 30, 2001
    NIH
    CD95 (FAS) LIGAND AND IMMUNE PRIVILEGED TISSUE
    Role: Principal Investigator
    R44AI040394     (DUKE, RICHARD C)Sep 30, 1996 - Jul 31, 2002
    NIH
    FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT
    Role: Principal Investigator
    R43AI040394     (DUKE, RICHARD C)Sep 30, 1996 - Mar 31, 1997
    NIH
    FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT
    Role: Principal Investigator
    R01AI029553     (DUKE, RICHARD C)May 1, 1990 - Apr 30, 1994
    NIH
    SELF-RECOGNITION BY T CELLS
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Benam CH, Baler G, Duke R, McNeal DM, Muller KA, Bodine C, Morrato EH, Sokol RJ. Fostering innovation at Academic Medical Centers: The Case of University of Colorado Anschutz Medical Campus. J Clin Transl Sci. 2021; 5(1):e148. PMID: 34527288.
      View in: PubMed
    2. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 2012 Dec; 20(12):2234-43. PMID: 22850679.
      View in: PubMed
    3. Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine. 2010 Aug 23; 28(37):6028-35. PMID: 20619375.
      View in: PubMed
    4. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007 Feb 09; 25(8):1452-63. PMID: 17098335.
      View in: PubMed
    5. Franzusoff A, Duke RC, King TH, Lu Y, Rodell TC. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther. 2005 Apr; 5(4):565-75. PMID: 15934834.
      View in: PubMed
    6. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC, Franzusoff A. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004 Aug 01; 64(15):5084-8. PMID: 15289309.
      View in: PubMed
    7. Modiano JF, Sun J, Lang J, Vacano G, Patterson D, Chan D, Franzusoff A, Gianani R, Meech SJ, Duke R, Bellgrau D. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol. 2004 Jul; 112(1):54-65. PMID: 15207782.
      View in: PubMed
    8. Duke RC. Methods of analyzing chromatin changes accompanying apoptosis of target cells in killer cell assays. Methods Mol Biol. 2004; 282:43-66. PMID: 15105556.
      View in: PubMed
    9. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC, Modiano JF. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003 Sep; 10(9):726-36. PMID: 12944992.
      View in: PubMed
    10. Zuraff-Perryman LA, Duke RC, Setser E, Nelson DP, Bellgrau D. Murine heart transgenic Fas ligand expression protects against allograft rejection. Transplant Proc. 2002 Dec; 34(8):3396-8. PMID: 12493481.
      View in: PubMed
    11. Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA. Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol. 2002 Sep; 119(3):556-61. PMID: 12230495.
      View in: PubMed
    12. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001 May; 7(5):625-9. PMID: 11329066.
      View in: PubMed
    13. Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000 May; 105(9):1199-208. PMID: 10791994.
      View in: PubMed
    14. Duke RC. Methods of analyzing chromatin changes accompanying apoptosis of target cells in killer cell assays. Methods Mol Biol. 2000; 121:125-43. PMID: 10818722.
      View in: PubMed
    15. Hedlund TE, Duke RC, Miller GJ. Three-dimensional spheroid cultures of human prostate cancer cell lines. Prostate. 1999 Nov 01; 41(3):154-65. PMID: 10517873.
      View in: PubMed
    16. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem. 1999 Sep; 199(1-2):169-78. PMID: 10544965.
      View in: PubMed
    17. Lin B, Williams-Skipp C, Tao Y, Schleicher MS, Cano LL, Duke RC, Scheinman RI. NF-kappaB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differ. 1999 Jun; 6(6):570-82. PMID: 10381655.
      View in: PubMed
    18. Duke RC, Newell E, Schleicher M, Meech S, Bellgrau D. Transplantation of cells and tissues expressing Fas ligand. Transplant Proc. 1999 May; 31(3):1479-81. PMID: 10330975.
      View in: PubMed
    19. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 1999 Feb; 6(2):175-82. PMID: 10200564.
      View in: PubMed
    20. Bellgrau D, Duke RC. Apoptosis and CD95 ligand in immune privileged sites. Int Rev Immunol. 1999; 18(5-6):547-62. PMID: 10672501.
      View in: PubMed
    21. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998 Dec; 4(12):1377-82. PMID: 9846574.
      View in: PubMed
    22. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, Hunger SP, Duke RC, DeGregori J. Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13159-64. PMID: 9789058.
      View in: PubMed
    23. Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate. 1998 Jul 01; 36(2):92-101. PMID: 9655261.
      View in: PubMed
    24. Nash PB, Purner MB, Leon RP, Clarke P, Duke RC, Curiel TJ. Toxoplasma gondii-infected cells are resistant to multiple inducers of apoptosis. J Immunol. 1998 Feb 15; 160(4):1824-30. PMID: 9469443.
      View in: PubMed
    25. Norris DA, Middleton MH, Whang K, Schleicher M, McGovern T, Bennion SD, David-Bajar K, Davis D, Duke RC. Human keratinocytes maintain reversible anti-apoptotic defenses in vivo and in vitro. Apoptosis. 1997; 2(2):136-48. PMID: 14646548.
      View in: PubMed
    26. Duke RC, Ojcius DM, Young JD. Cell suicide in health and disease. Sci Am. 1996 Dec; 275(6):80-7. PMID: 8923763.
      View in: PubMed
    27. Miranda L, Wolf J, Pichuantes S, Duke R, Franzusoff A. Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):7695-700. PMID: 8755538.
      View in: PubMed
    28. Hofer MF, Newell K, Duke RC, Schlievert PM, Freed JH, Leung DY. Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis. Proc Natl Acad Sci U S A. 1996 May 28; 93(11):5425-30. PMID: 8643591.
      View in: PubMed
    29. Berggren RE, Wunderlich A, Ziegler E, Schleicher M, Duke RC, Looney D, Fang FC. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15; 10(5):489-95. PMID: 8548327.
      View in: PubMed
    30. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19; 377(6550):630-2. PMID: 7566174.
      View in: PubMed
    31. Walsh P, Dorner A, Duke RC, Su LJ, Glode LM. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma. J Natl Cancer Inst. 1995 Jun 07; 87(11):809-16. PMID: 7791230.
      View in: PubMed
    32. Norris DA, Duke R, Whang K, Middleton M. Immunologic cytotoxicity in alopecia areata: apoptosis of dermal papilla cells in alopecia areata. J Invest Dermatol. 1995 May; 104(5 Suppl):8S-9S. PMID: 7738399.
      View in: PubMed
    33. Kozono Y, Duke RC, Schleicher MS, Holers VM. Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis. Eur J Immunol. 1995 Apr; 25(4):1013-7. PMID: 7737272.
      View in: PubMed
    34. Duke RC, Witter RZ, Nash PB, Young JD, Ojcius DM. Cytolysis mediated by ionophores and pore-forming agents: role of intracellular calcium in apoptosis. FASEB J. 1994 Feb; 8(2):237-46. PMID: 8119494.
      View in: PubMed
    35. Duke RC. Apoptosis in cytotoxic T lymphocytes and their targets. Semin Immunol. 1992 Dec; 4(6):407-12. PMID: 1286167.
      View in: PubMed
    36. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992; 10:267-93. PMID: 1590988.
      View in: PubMed
    37. Cohen CJ, Duke RC, Sellins KS. Stimulation by superantigen. Nature. 1991 Jul 18; 352(6332):199-200. PMID: 1857413.
      View in: PubMed
    38. Alles A, Alley K, Barrett JC, Buttyan R, Columbano A, Cope FO, Copelan EA, Duke RC, Farel PB, Gershenson LE, et al. Apoptosis: a general comment. FASEB J. 1991 May; 5(8):2127-8. PMID: 2022310.
      View in: PubMed
    39. Duke RC, Persechini PM, Chang S, Liu CC, Cohen JJ, Young JD. Purified perforin induces target cell lysis but not DNA fragmentation. J Exp Med. 1989 Oct 01; 170(4):1451-6. PMID: 2794864.
      View in: PubMed
    40. Duke RC. Self recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. J Exp Med. 1989 Jul 01; 170(1):59-71. PMID: 2787386.
      View in: PubMed
    41. Duke RC, Sellins KS, Cohen JJ. Cytotoxic lymphocyte-derived lytic granules do not induce DNA fragmentation in target cells. J Immunol. 1988 Oct 01; 141(7):2191-4. PMID: 2844898.
      View in: PubMed
    42. Pettijohn DE, Pfenninger O, Brown J, Duke R, Olsson L. Tumorigenic human squamous lung cancer cells have defined cell surface carbohydrates that are absent from nontumorigenic cells. Proc Natl Acad Sci U S A. 1988 Feb; 85(3):802-6. PMID: 3422461.
      View in: PubMed
    43. La Rosa FG, Talmage DW, Zlotnik A, Duke RC. Cellular and molecular immunology of tissue transplantation. Revis Biol Celular. 1988; 17:1-114. PMID: 3071826.
      View in: PubMed
    44. Duke RC, Cohen JJ, Chervenak R. Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells. J Immunol. 1986 Sep 01; 137(5):1442-7. PMID: 2943792.
      View in: PubMed
    45. Duke RC, Cohen JJ. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res. 1986; 5(4):289-99. PMID: 2946903.
      View in: PubMed
    46. Cohen JJ, Duke RC, Chervenak R, Sellins KS, Olson LK. DNA fragmentation in targets of CTL: an example of programmed cell death in the immune system. Adv Exp Med Biol. 1985; 184:493-508. PMID: 2994413.
      View in: PubMed
    47. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol. 1984 Jan; 132(1):38-42. PMID: 6317746.
      View in: PubMed
    48. Duke RC, Chervenak R, Cohen JJ. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci U S A. 1983 Oct; 80(20):6361-5. PMID: 6312454.
      View in: PubMed
    Duke's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (279) concept(s)
    _
    Co-Authors Expand Description
    See all (9) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)